Stamford Pharmaceuticals announces the first patient on-study to be treated with ASN-002
Stamford Pharmaceuticals Inc and Ascend Biopharmaceuticals Ltd (its Australian affiliate) announces the first patient on-study to be treated with ASN-002 […]
Stamford Pharmaceuticals Inc Announces Clinical Collaboration with Roche
Stamford Pharmaceuticals Inc Announces Clinical Collaboration with Roche to Evaluate SP-002 in Combination with vismodegib in Patients with basal cell […]
Stamford Pharmaceuticals announced receiving HREC approval for the commencement of the initial phase of its registration program
Stamford Pharmaceuticals announced today receiving ethics approval for the Pilot phase of its registration program. The program will commence initially […]
Stamford Pharmaceuticals announced today that Associate Professors Greg Siller and Sherrif Ibrahim will be Principal Investigators for the company’s initial Pilot phase of its registration program in Australia and the US
August 1st, 2019 Stamford Pharmaceuticals announced today the engagement with Assoc. Professors Greg Siller and Sherrif Ibrahim to serve as […]